drmabehara

For generations, inherited retinal diseases (IRDs) were considered untreatable, leaving countless individuals to face a future of progressive vision loss and blindness. These conditions, such as Retinitis Pigmentosa, Leber Congenital Amaurosis (LCA), and Stargardt disease, are caused by a single genetic mutation. However, a revolutionary scientific breakthrough—gene therapy—is transforming this once-bleak outlook into a horizon of hope. In 2025, while still in its early stages in India, this innovative treatment is offering a chance to correct the root cause of these devastating diseases and preserve vision. Inherited retinal diseases are a group of disorders where a faulty gene prevents retinal cells from functioning correctly, leading to their progressive degeneration. Because the underlying problem is genetic, traditional treatments have been limited to managing symptoms, but gene therapy takes a fundamentally different and more powerful approach. How Gene Therapy Works: Correcting the Blueprint Gene therapy aims to deliver a healthy, functional copy of a mutated gene to the affected cells in the retina. The process typically involves: Diagnosis: A thorough genetic diagnosis is the first crucial step. Genetic testing identifies the specific gene mutation causing the disease. Since a single IRD can be caused by mutations in many different genes, pinpointing the exact genetic flaw is essential for developing a targeted therapy. The Delivery Vehicle (Vector): Scientists use a modified, harmless virus, called a vector, to carry the healthy gene into the retinal cells. These vectors, most commonly adeno-associated viruses (AAVs), are excellent at getting into cells and delivering their genetic cargo without causing illness. The Procedure: The gene therapy is administered directly into the eye through a minimally invasive surgical procedure. The two most common methods are: Subretinal Injection: The vector is injected into the space just beneath the retina, allowing it to deliver the healthy gene directly to the light-sensing photoreceptor cells and the retinal pigment epithelium (RPE), which are often the primary targets. Intravitreal Injection: The vector is injected into the jelly-like substance (vitreous) in the center of the eye. This is a simpler procedure and is often used for diseases that affect the inner layers of the retina. The Landmark Success of LUXTURNA™ The first FDA-approved gene therapy for an inherited disease, LUXTURNA™ (voretigene neparvovec-rzyl), set a new precedent. It treats a specific form of LCA caused by mutations in the RPE65 gene. The treatment involves a one-time injection of a vector carrying a working copy of the RPE65 gene. This breakthrough has demonstrated the potential to not only halt vision loss but, in some cases, significantly improve vision, particularly in low-light conditions. The Hope for the Future in India While global access to gene therapy is a work in progress, the future in India is looking more promising. Institutions like L.V. Prasad Eye Institute and Narayana Nethralaya are at the forefront of this research. Efforts are underway to: Establish Genetic Databases: Researchers are working to identify the specific genetic mutations prevalent in the Indian population. This is critical because certain mutations can be unique to a particular community. Initiate Clinical Trials: Human trials for specific IRDs are being initiated, paving the way for the indigenous development and use of gene therapies. Improve Accessibility: The current cost of gene therapy is a major barrier. Researchers in India are focused on developing indigenous vectors and production processes to make these life-changing treatments more affordable and accessible to a larger population. Important Considerations and the Road Ahead Gene therapy is not a cure for all inherited retinal diseases. Its effectiveness depends on several factors: The Specific Gene: The therapy must be tailored to the exact gene mutation. Timing: Gene therapy can’t restore cells that have already been lost. It works by preserving and restoring the function of remaining cells. This means that early diagnosis and intervention are critical. Not for All Cases: It’s most effective for “loss-of-function” genetic disorders where a broken gene can be replaced with a healthy copy. Different genetic conditions require different approaches, such as gene editing. Gene therapy for inherited retinal diseases is a new frontier in medicine. It is a testament to what can be achieved by targeting a disease’s root cause. For families in India grappling with the devastating reality of inherited vision loss, this new era of precision medicine offers a powerful and genuine reason for hope.

For patients in India diagnosed with glaucoma, the journey often begins with a prescription for eye drops to control the pressure inside the eye (intraocular pressure, or IOP). For many, this is a sufficient and long-term solution. However, when eye drops and even laser treatments are not enough to halt the progression of the disease, surgery becomes a critical and often life-saving option for preserving remaining vision, especially in advanced glaucoma cases. Glaucoma is a progressive optic neuropathy, and once the optic nerve is damaged, the resulting vision loss is permanent. This makes the primary goal of treatment to aggressively lower IOP and prevent further damage. In advanced stages, when the disease is not responding to less-invasive methods, more definitive surgical intervention is required to achieve a consistently low IOP and halt the relentless progression of vision loss. Understanding the Need for Surgery in Advanced Cases In advanced glaucoma, the eye’s natural drainage system is often severely compromised, and the optic nerve is already fragile and highly susceptible to even minor pressure fluctuations. In these situations, a surgical procedure is no longer just a “next step” but often the most reliable way to achieve the very low target IOP necessary to protect the optic nerve from further irreversible damage. Key Surgical Options for Advanced Glaucoma While there are various surgical procedures, the most common and effective ones for advanced glaucoma cases in India in 2025 are: Trabeculectomy (Trab): Often considered the “gold standard” for glaucoma surgery, trabeculectomy is a filtering microsurgery. How it Works: The surgeon creates a new drainage channel or a small opening in the sclera (the white part of the eye). This opening allows the fluid inside the eye to bypass the blocked natural drainage system and collect in a small, external “blister” or “bleb” under the conjunctiva (the clear membrane covering the white of the eye). The fluid from this bleb is then reabsorbed by the body. The Role in Advanced Glaucoma: Trabeculectomy is highly effective at achieving a very low IOP and is often the first choice for advanced glaucoma. While it is more invasive than other options and has a longer recovery period, its ability to significantly and consistently lower pressure makes it invaluable for halting disease progression. Glaucoma Drainage Devices (Tube Shunts): How they Work: These procedures involve implanting a tiny tube or shunt into the eye to drain excess fluid. The tube directs fluid from the inside of the eye to a small plate or reservoir placed on the outside of the eye (often hidden under the eyelid). The fluid then collects on this plate and is reabsorbed. Common devices include the Ahmed Glaucoma Valve and Baerveldt Glaucoma Implant. The Role in Advanced Glaucoma: Tube shunts are often used when trabeculectomy has failed or is not a suitable option, such as in patients with certain types of glaucoma (like neovascular glaucoma or those with previous surgeries). They provide a reliable, long-term solution for maintaining low IOP, and are a critical tool in managing complex and advanced cases. Cyclophotocoagulation (CPC): How it Works: This laser procedure, often reserved for advanced or refractory cases, uses a laser to treat the ciliary body, the part of the eye that produces the fluid. By partially disabling these fluid-producing tissues, the procedure reduces the amount of fluid in the eye, thereby lowering the pressure. The Role in Advanced Glaucoma: CPC is typically a “last resort” procedure for patients with severe glaucoma that has not responded to other treatments. It is often used to control pain and preserve what little vision remains in a severely damaged eye. What to Expect with Glaucoma Surgery Outpatient Procedure: Most of these surgeries are performed on an outpatient basis in a hospital or specialized surgical center. Anesthesia: They are typically performed under local anesthesia with sedation, so you will be comfortable and won’t feel pain. Recovery: Recovery time varies, but patients will need to use prescribed eye drops, attend frequent follow-up appointments, and avoid strenuous activities for several weeks. Potential Risks: As with any surgery, there are risks, including infection, bleeding, and the potential for the pressure to be too low or too high. However, for advanced glaucoma, the benefits of halting vision loss often far outweigh these risks. The Bottom Line for Indian Patients In India, where glaucoma is a major cause of irreversible blindness, understanding the role of surgery is paramount. For patients whose glaucoma is no longer controlled by eye drops and laser treatments, surgery provides the most powerful tool to protect their remaining vision. A frank discussion with a glaucoma specialist about your condition, the risks and benefits of surgery, and what to expect from the procedure can empower you to make an informed decision and take a definitive step toward safeguarding your sight.